FDA issues warning on 4 widely-used asthma drugs

Feb 18, 2010 By LAURAN NEERGAARD , AP Medical Writer

(AP) -- The government is issuing new restrictions on some widely used long-acting asthma drugs, saying they should never be used without other asthma controllers to prevent a lifethreatening risk.

Four medications - Foradil, Serevent, Advair and Symbicort - contain an ingredient that relaxes muscles in the lung's airways. While they're very helpful for some patients, the way they work also may mask symptoms that can trigger serious attacks. It's a particular concern for children.

The ordered new labels saying the drugs should be used for the shortest possible duration - and only together with other medications such as inhaled steroids that work differently, by relieving airway inflammation.

Explore further: Determine patient preferences by means of conjoint analysis

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Asthma risk increases in children treated for HIV

Jul 01, 2008

Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor ...

More pounds equals worse asthma?

May 22, 2007

A new study presented at the American Thoracic Society 2007 International Conference finds that obese people are significantly more likely to have persistent or severe persistent asthma than their thinner counterparts.

Recommended for you

Determine patient preferences by means of conjoint analysis

16 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0